Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech drug approval

FDA Approves Daraxonrasib for Pancreatic Cancer

Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Sep 11, 2026

Sentiment
25
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval gives Revolution Medicines a first-in-class commercial product in a high-unmet-need oncology market, supporting revenue expectations and validating its KRAS-targeting platform for future indications. It also raises competitive pressure and investment interest across the KRAS and pancreatic cancer drug development space, while payers and patients focus on the roughly $39,800 monthly price.

pharmaceuticals biotechnology healthcare

The United States — Food and Drug Administration approved daraxonrasib, a first-of-its-kind daily pill for metastatic pancreatic cancer, sold by Revolution Medicines under the brand name Rasonque. The drug blocks mutated KRAS proteins that drive tumor growth in more than 90% of pancreatic cancer cases, an approach that had eluded drugmakers for decades. In a company-funded trial of 500 patients whose cancer had progressed after prior treatment, median overall survival nearly doubled to 13.2 months versus 6.7 months for chemotherapy, with milder side effects such as rash, diarrhea and fatigue. A one-month supply is priced at approximately $39,800. The FDA granted expedited approval more than six months ahead of its target date, following a Breakthrough Therapy designation in June 2025 and an expanded access program that has already provided the drug free of charge to more than 2,000 patients since May. The American Cancer Society estimates about 67,000 new US cases and more than 52,000 deaths from pancreatic cancer annually, with a five-year survival rate of roughly 12-13%. Researchers at Dana–Farber Cancer Institute, Fred Hutchinson Cancer Center and City of Hope welcomed the approval and expect the KRAS-targeting approach to spur trials in other tumor types, including lung cancer. Former senator Ben Sasse publicly described reduced pain while taking the drug, boosting public interest.

stock
Secures first approval and commercial launch of daraxonrasib under the Rasonque brand at about $39,800 per month, validating its KRAS molecular glue platform and opening expansion into other cancers.
Importance 100.0 Sentiment 70.0
govactor
Granted expedited approval of daraxonrasib more than six months ahead of its target date, reinforcing its accelerated-review posture for serious diseases.
Importance 90.0 Sentiment 10.0
cnt
US patients gain a new treatment option for a leading cause of cancer death, with roughly 67,000 new cases and 52,000 deaths annually.
Importance 25.0 Sentiment 5.0
ngo
Provided epidemiology cited across coverage, underscoring the large patient population and high mortality that define the drug's market opportunity.
Importance 20.0 Sentiment 0.0
ngo
Its physician called the approval one of the most anticipated, adding clinical endorsement of the drug's significance.
Importance 20.0 Sentiment 5.0
ngo
Its researcher said the approval opens doors for other companies, highlighting spillover interest in KRAS therapies.
Importance 15.0 Sentiment 5.0
per
His public account of reduced pain while taking daraxonrasib helped drive expanded access and public attention ahead of approval.
Importance 15.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.